Skip to main content
. 2023 Jan 17;12(2):154. doi: 10.3390/pathogens12020154

Table 1.

Non-specific approaches to treating acute RSV bronchiolitis.

Product Name Mode of Administration/Mechanism of Action Recommendation
Mucus therapies
Deoxyribonuclease (hrDNase) Nebulized solution
Mucolytic compound
Cleaves extracellular DNA
Not recommended [35]
May be considered as a therapeutic option for atelectasis in severe cases, when conventional therapy is unsuccessful [36]
N-acetylcysteine Nebulized solution
Poor bioavailability of oral preparation [37]
Mucolytic compound
Hydrolyzes disulfide bonds of mucus proteins
Antioxidant properties [38]
Insufficient data—further studies needed
Not recommended
3% hypertonic saline Nebulized solution
Creates osmotic gradient and pulls water into the mucus layer
Improves ciliary activity
Stimulates cough
May reduce airway edema [39]
May reduce the risk of hospitalization in the ED setting [40]
Not recommended for inpatient management
May modestly reduce the duration of admission for infants admitted >72 h—further studies needed [40,41]
Bronchodilators
Salbutamol, albuterol, etc. Nebulized solution
β-2 adrenergic receptor agonist, relaxes smooth muscle and opens airways
Not recommended [33]
Can be trialled to assess the response in certain cases and given where a benefit is seen
Epinephrine Nebulized solution
Some β-2 adrenergic effects
Vasoconstriction due to α-1 adrenergic receptor effects also decrease airway edema
May reduce risk of hospitalization in the ED setting [42]
Not recommended [43]
Therapies targeting inflammation
Glucocorticoids
(dexamethasone, prednisolone, budesonide, etc.)
Oral solution, inhaled or nebulized preparations
Broad spectrum anti-inflammatory
Repress the expression of pro-inflammatory cytokines
Not recommended [44,45]
Could be considered where reactive airway disease is strongly suspected (asthma, bronchopulmonary dysplasia, etc.), but no good evidence
Leukotriene inhibitors
(montelukast, etc.)
Oral solution
Inhibit leukotrienes, which are endogenous mediators of inflammation [46]
Poor evidence, not recommended [47]
Manual therapies
Chest physiotherapy Chest percussion, suction
Aids in the clearance of secretions
Thought to decrease ventilatory effort for infants on the severe end of the disease spectrum
Not routinely recommended [48]
Can be considered when relevant comorbidities are present (neuromuscular conditions, etc.) [49]